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Fatal pulmonary complications in an immunodeficient child with 
chronic active Epstein-Barr virus infection
Śmiertelne powikłania płucne u dziecka z niedoborem odporności i przewlekłym 
aktywnym zakażeniem wirusem Epsteina-Barra
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Abstract
Primary Epstein-Barr virus infection in children typically presents as infectious mononucleosis and in immunocompetent individu-
als severe pneumonitis proves to be a rare complication. Chronic active Epstein-Barr virus infection (CAEBV) is associated with 
multiple life-threatening conditions, including interstitial lung disease with fibrosis and lymphoid and lymphohistiocytic infiltra-
tions. We report on a pediatric patient in whom CAEBV resulted in severe pneumopathy with a fatal outcome.
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Streszczenie
Pierwotne zakażenie wirusem Epsteina-Barra u dzieci manifestuje się najczęściej jako mononukleoza zakaźna i u osób immuno-
kompetentnych zapalenie płuc o ciężkim przebiegu jest rzadkim powikłaniem. Przewlekłe aktywne zakażenie wirusem Epsteina
-Barr (CAEBV) jest związane z licznymi zagrażającymi życiu powikłaniami, takimi jak śródmiąższowa choroba płuc z włóknieniem 
i nacieki limfohistiocytarne. W pracy przedstawiono przypadek dziecka z CAEBV i powikłaniami płucnymi o śmiertelnym przebiegu. 
Pneumonol. Alergol. Pol. 2014; 82: 364–367 
Słowa kluczowe: wirus Epsteina-Barra, zapalenie płuc, dzieci
Epstein-Barr virus-associated clinical syndromes
Epstein-Barr virus (EBV) belongs to the Her-
pesviridae family (human herpesvirus 4, HHV-4) 
and its acquisition, like other herpesviruses, 
results in lifelong infection after the initial viral 
replication has been contained. In the vast majo-
rity of healthy individuals, the EBV infections are 
subclinical and cause no disease owing to the de-
licate balance between the host’s immune system, 
limiting viral replication and the persistence and 
transmission of the virus. Inappropriate control 
of viral replication leads to chronic active EBV 
(CAEBV) infection, characterised by infectious 
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mononucleosis (IM)-like symptoms, high anti-EBV 
antibody titres and detection of EBV genomes 
DNA in affected tissues, including peripheral 
blood. More severe and fatal clinical manifesta-
tions (SCAEBV) occur predominantly in children 
under the age of 15 years and are accompanied 
by a tendency toward pancytopenia as well as 
T- and NK-cell lymphoproliferative disorders and 
hemophagocytic lymphohistiocytosis [1].
In this paper we report on pediatric patient 
in whom CAEBV resulted in severe pulmonary 
complications with fatal outcome.
Fatal pulmonary complications  
in a child with CAEBV infection
A 15-year-old boy was referred to the pe-
diatric pneumonology, allergology and clinical 
immunology department of the university hospi-
tal because of persistent fever and lower airway 
infection with increasing signs of respiratory and 
circulatory insufficiency.
He was the first child of middle-aged, non-
consanguineous parents, born from the second 
pregnancy in the 38th week of gestation; the 
perinatal period was uncomplicated. Since the 
second year of life he gradually presented with 
multiorgan autoimmune disorders – celiac dise-
ase, hypothyroidism, hypopituitarism and gro-
wth hormone deficiency as well as autoimmune 
hepatitis with positive antinuclear and smooth 
muscle antibodies (ANA and SMA, respectively). 
He required immunosuppressive treatment with 
systemic corticosteroids (prednisone, methyl-
prednisolone) and azathioprine, along with sub-
stitution therapy with thyroxin and growth hor-
mone. At the age of four years he underwent the 
surgical treatment of a non-neoplastic tumour of 
the right temporal lobe resulting in drug-resistant 
epilepsy. Since early infancy he had suffered 
from recurrent airway infections – pharyngitis, 
bronchitis and otitis media, which led to the 
formation of a cholesteatoma requiring surgical 
removal. Furthermore, at the age of ten, a cochlear 
implant was engrafted to the left ear because of 
deep sensory-neural hypoacusis.
Two years later, the boy developed a disse-
minated HSV (herpes simplex virus) infection 
with papular eruptions on the skin and mucous 
membranes. Simultaneously, an infection with 
Epstein-Barr virus was diagnosed based on po-
sitive anti-EBV antibodies (VCA IgM and IgG, 
EA IgG) and detection of EBV-DNA in peripheral 
blood mononuclear cells (3,727 × 104 copies/
mL) and with cytomegalovirus (CMV) because 
of elevated anti-CMV IgM antibody titres and 
positive CMV-DNA in qualitative polymerase 
chain reaction (PCR) of peripheral blood and 
urine. Treatment with ganciclovir, followed by 
oral aciclovir led to clinical improvement as well 
as to negative PCR for CMV-DNA. Along with 
antiviral therapy, intravenous polyvalent immu-
noglobulin transfusions and antibiotic prophyla-
xis with amoxicillin, followed by azithromycin, 
were instituted because of the demonstrated 
IgG4 subclass deficiency. Major immunoglobulin 
isotypes, complement component levels as well 
as B- and T-cell subsets in peripheral blood flow 
cytometric immunophenotyping did not show 
any significant abnormalities. Until the age of 15 
years the boy suffered from recurrent respiratory 
tract infections which were successfully treated 
in an outpatient setting.
On admission to hospital, the child presented 
with fever, dyspnea, tachypnea, candidal stoma-
titis and dental caries, symptoms of bronchial 
obstruction and disseminated bilateral fine rales 
on auscultation as well as hepatomegaly. In gaso-
metry hypoxemia, desaturation and hypocapnia 
were found (pO2: 52.3 mm Hg, sO2: 82.0%, pCO2: 
30.4 mm Hg, respectively). Laboratory tests re-
vealed pancytopenia (leukopenia — WBC 0.16 
× 103/μL, anemia — HGB 8.6 g/dL, RBC 3.02 × 
106/μL, thrombocytopenia 17.0 × 103/μL), lym-
phopenia 0.002 × 103/μL (12.5%) in peripheral 
blood smear, significantly elevated markers of 
inflammation (C-reactive protein 39.19 mg/dL, 
procalcitonin > 0.5 ng/mL, ferritin 158.2 ng/mL, 
d-dimer 1.84 mg/L) and a high EBV-DNA load 
in peripheral blood (9.11 × 104 copies/mL). 
In peripheral blood lymphocyte flow cytome-
tric immunophenotyping, decreased absolute 
count and relative number of B, T CD4 and CD8 
as well as NK cells were revealed. On a chest 
radiograph, disseminated bilateral patchy and 
stranded parenchymal and interstitial infiltra-
tions with blurred borders of the heart shape 
and the diaphragm were present (Fig. 1). HRCT 
(high-resolution computed tomography) imaging 
showed massive confluent patchy opacities in 
both lungs, with irregular cavities indicating a 
decay of the lung parenchyma, accompanied by 
fibrosis and dilation of the peripheral portions of 
the bronchi and mediastinal lymphadenopathy 
(Fig. 2). Infections with respiratory syncytial virus 
(RSV) A and B, rhinovirus A and B, adenovirus, 
metapneumovirus, influenza A (including A 
H1N1) and B viruses, parainfluenza 1, 2 and 3 
viruses, coronavirus OC43 and 229E, Mycoplasma 
pneumoniae, Chlamydophila pneumoniae, Le-
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gionella pneumophila and Pneumocystis jiroveci 
were excluded on negative PCR examinations of 
tracheal aspirate samples and infection with hu-
man immunodeficiency virus (HIV) was excluded 
on a negative ELISA test of peripheral blood. 
Sputum and blood cultures did not show any 
pathological bacterial flora. Despite intensive, 
multiple drug therapy with aciclovir, antibiotics 
(ciprofloxacin, vancomycin), trimethoprim/ 
/sulfamethoxazole, antifungal agent (flucona-
zole), immunoglobulins and systemic cortico-
steroids, deterioration of the child’s state and 
development of the respiratory and circulatory 
insufficiency were observed. The patient died in 
the pediatric anesthesiology and intensive care 
unit because of multiorgan failure.
Discussion
Impaired immune control of the infection 
resulting from primary immune deficiencies may 
lead to significant EBV-related clinical pathology, 
including a life-threatening primary infection and 
EBV-associated lymphoproliferative disorders [2].
In healthy young children, the primary EBV 
infection is usually asymptomatic, and in 50% of 
adolescents it presents as an infectious mononuc-
leosis (IM). Complications resulting from viral 
tissue invasion or from excessive immune-media-
ted damage are uncommon. These include upper 
airway obstruction, meningoencephalitis and 
other neurological complications, pancreatitis, 
pericarditis, myocarditis, pneumonitis and sple-
nic rupture, as well as autoimmune phenomena 
such as hemolytic anemia and thrombocytopenia 
[3]. In immunocompromised children, such as 
those affected by the X-linked lymphoprolife-
rative syndrome (XLPS), with mutations in the 
gene encoding the signalling lymphocyte activa-
tion molecule (SLAM-associated protein, SAP), 
a fulminating, fatal primary EBV infection may 
occur [4].
Chronic active EBV infection may result in life- 
-threatening complications, such as accelerated 
hematological phase also referred to as hemopha-
gocytic lymphohistiocytosis, hematological mali-
gnancies and hepatic failure [5]. EBV pneumonia 
is rare in immunocompetent subjects [6–8]. While 
mild, usually asymptomatic pneumonitis occurs 
in about 5-10% of all immunocompetent cases 
of infectious mononucleosis; severe pulmonary 
involvement predominantly in the form of inter-
stitial pneumonitis has also been reported to date 
[9–11]. CAEBV infection has been associated with 
often life-threatening pulmonary complications 
most often in adult patients; however, severe fatal 
EBV-related prominent atypical lymphoid or lym-
phohistiocytic infiltrates have also been reported 
in an immunodeficient pediatric patient [12] as 
well as in immunocompetent young children [13]. 
Certainly, an immunosuppressive therapy with 
systemic corticosteroids and azathioprine may 
have had an important impact on the immune re-
sponse, defective control of viral replication and 
development of CAEBV infection in the reported 
case. The boy presented with severe systemic in-
flammatory response evolving signs of hemopha-
gocytic syndrome as well as unusually extensive 
parenchymal and interstitial pneumopathy with 
necrosis. Since bacteria such as Streptococcus 
pneumoniae or Staphylococcus aureus are the 
most frequent etiological factors of necrotic pneu-
Figure 1. Chest radiograph showing disseminated bilateral patchy and 
stranded parenchymal and interstitial infiltrations with blurred borders 
of the heart shape and the diaphragm
Figure 2. Transaxial HRCT imaging of the chest showing massive 
confluent patchy opacities  in both lungs, with irregular cavities in-
dicating collapse of the lung parenchyma, accompanied by fibrosis 
and dilation of the peripheral portions of the bronchi and mediastinal 
lymphadenopathy
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monia in children, which may be characterised 
by a congenial clinical course and radiographic 
presentation [14, 15], infections with these patho-
gens must primarily be taken into account in the 
differential diagnosis despite negative cultures. 
Among other causative agents, such bacteria as 
Klebsiella pneumoniae, Pseudomonas aeruginosa, 
and Acinetobacter lwoffii must also be considered 
in differential diagnostics [16]. In children with 
viral respiratory infections, in particular with 
recently emerged pandemic influenza A (H1N1), 
the interactive mechanisms between viruses and 
bacteria predispose to bacterial superinfections 
and development of necrotic pulmonary lesions 
[17]. In immunocompromised children, fungal 
infections with Candida, Aspergillus fumigatus, 
Cryptococcus neoformans as well as Scedosporium 
prolificans must be taken into account as caus-
ative agents of necrotic pneumonia [18].
In conclusion, CAEBV infection may result 
in pulmonary involvement with a fatal outcome; 
therefore, any suspicion of its presence should 
lead to immediate investigation in order to secure 
an early diagnosis and treatment.
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